Scaling Human Bioequivalence: The New Frontier of Organoids and AI with Daniel Delubac

Join Daniel Delubac, CEO of IORGANBIO, for a deep dive into the breakthrough technologies reshaping modern medicine. From non-invasive prenatal testing to the first AI-agentic platforms for synthetic chemistry, Daniel has been at the center of the world's most significant biotech innovations. In this episode, we explore how IORGANBIO is merging first-principles engineering with AI to manufacture human bioequivalent cells and organoids at scale—replacing outdated animal models and paving the way for accessible, $n$-of-one regenerative medicine.🎯 Insights You’ll Learn:✓ The Power of NAMs: Why organoids are the key to moving past animal testing in drug discovery✓ AI-Driven Modeling: Leveraging AI to generate high-fidelity cell and organoid models✓ Manufacturing Challenges: Solving the bottlenecks in biopharma process development✓ Advanced Therapies: The reality of $n$-of-one drug development and cell therapy✓ Bioequivalent Infrastructure: Building the tools to manufacture human cells at population scale✓ Lessons from the Frontlines: Insights from shaping Counsyl, Guardant Health, and Freenome✓ The Future of Regeneration: How bioengineering will soon restore lost human function🌍 Why This Matters:The traditional drug discovery pipeline is slow, expensive, and often fails because animal models do not accurately predict human outcomes. Daniel Delubac is leading a shift toward "human bioequivalence." By combining robotics, AI, and biological engineering, IORGANBIO is building the infrastructure necessary to create high-fidelity human models that can be manufactured reliably. This isn't just a marginal improvement; it is the foundation for a future where personalized, regenerative cures are accessible to everyone, not just the elite.👤 Expert Background:• Chief Executive Officer of IORGANBIO, redefining cell-based manufacturing• PhD in Biomedical Engineering from Carnegie Mellon University• Instrumental in the growth of Counsyl, Guardant Health, Freenome, and Xilis• Expert in the intersection of AI-agentic platforms and synthetic chemistry• Visionary builder of breakthrough biotech across robotics, software, and physics🎙️ Hosted by Gary Fowler, CEO of GSD Venture Studios — global AI entrepreneur, investor, and innovation leader spotlighting founders navigating the realities of building in the AI era.💡 Perfect For:Biotech founders, pharmaceutical executives, AI researchers, regenerative medicine specialists, and investors looking for the next "Category-of-One" in life sciences.🚀 Timely Topic:In 2026, the shift toward New Approach Methodologies (NAMs) is no longer optional—it is a regulatory and scientific necessity. The winners in biopharma will be those who can harness AI to model human biology with perfect fidelity before entering the clinic.Subscribe for more global founder conversations from GSD Venture Studios:👉 GSD Venture Studios: [https://gsdvs.com](https://gsdvs.com)#BiotechInnovation #Organoids #DrugDiscovery #AIinHealthcare #RegenerativeMedicine #BioEngineering #DanielDelubac #GaryFowler #GSDVentureStudios